There may be evidence that similar benefits might extend to patients with SLE. Meanwhile, according to Drucker, there are multiple trials of GLP-1 receptor agonists underway in PsA and several other rheumatic conditions that are exacerbated in people with increased BMI
76,81,96,97 The main factor contributing to the lack of greater investment in lixisenatide and other short-acting agents for MASLD may be their influence on metabolic function, including pharmacokinetic differences induced by a single-dose method and their effects on gastric emptying, 91 which could limit their effectiveness in improving glycolipid metabolism
For example, a patient whos been on semaglutide for six months or more may have significantly reduced alcohol consumption or stopped smoking spontaneously, outside any formal program, in a way that felt entirely unremarkable to them
Please confirm the statements below